Adalimumab, golimumab, infliximab, vedolizumab i tofacitinib per al tractament de la colitis ulcerosa en pacients adults
Ulcerative colitis (UC) is a chronic, recurrent inflammatory bowel disease (IBD) that affects the rectum and colon with varying degrees of extent and severity (proctitis, left or distal colitis, and extensive colitis or pancolitis). The incidence of UC is highly variable. The highest incidence rates are in Western countries. In Europe, the incidence varies greatly between countries, but it seems to have increased in the south and east in recent years. The estimated incidence and prevalence rate in Spain is 5.8 and 88.6 cases per 100,000 inhabitants, respectively.
Ulcerative colitis; Biological; JAK inhibitor
Programa d'Harmonització Farmacoterapèutica. Adalimumab, golimumab, infliximab, vedolizumab i tofacitinib per al tractament de la colitis ulcerosa en pacients adults. Barcelona: Servei Català de la Salut; 2019.
Use this identifier for quote and/or link this documenthttp://hdl.handle.net/11351/5082
This item appears in following collections
The following license files are associated with this item: